Oragenics Inc (OGEN AMEX) stock market data APIs
$0.4803
0.02(4.2%)
as of September 11, 2026
Try our APIs with
free plan!
Oragenics Inc Financial Data Overview
Price chart is built with
Anychart
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Lakewood Ranch, Florida.
Prev. Close
0.4803
Open
0.4961
High
0.4969
Low
0.4795
52 wk Range
0.48-1.45
Market Cap
2 157 K
P/E Ratio
0.4878
Shares Outstanding
4 512 K
EPS
-0.57
Beta
1.253
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Oragenics Inc data using free add-ons & libraries
Get Oragenics Inc Fundamental Data
Oragenics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -10 531 424
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-13
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Oragenics Inc News
New
Oragenics Activates Third Site For Phase 2a Of ONP-002 In Treating Concussions, Data By Q4 '26
(RTTNews) - Oragenics (OGEN), a clinical-stage biotechnology company, on Tuesday reported the activation of a third site in Australia for the Phase 2a trial for ONP-002 for the treatment of mild traum...
ORAGENICS PROVIDES INVESTOR UPDATE
A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Sarasota, FL, May 18, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) Dear Fellow Shareholders, Since our last investor update, Oragenics...
Oragenics Advances Phase IIa Trial Of ONP-002 For Concussion
(RTTNews) - Oragenics, Inc. (OGEN) has reported early progress in its Phase IIa clinical trial of ONP-002, a proprietary intranasal neurosteroid being developed for mild traumatic brain injury (mTBI),...
Oragenics Doses First Patient In Phase 2a Trial For Brain Injury Drug ONP-002
(RTTNews) - Oragenics Inc. (OGEN), a clinical-stage biotechnology company, on Monday announced the dosing of the first patient in the Phase 2a trial for ONP-002, the company's lead candidate for treat...
Get Oragenics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
